GLP-1 therapies are evolving beyond obesity treatment into a platform capable of transforming chronic disease management, healthcare spending, and investment across the healthcare ecosystem. As new clinical indications emerge and adoption accelerates, the biggest opportunities may extend far beyond pharmaceutical companies.

Introduction

Healthcare has witnessed few therapeutic breakthroughs capable of reshaping an entire ecosystem. GLP-1 receptor agonists are rapidly becoming one of them. Originally developed for the treatment of type 2 diabetes, these therapies have evolved into highly effective obesity treatments with the potential to redefine how chronic diseases are prevented, managed, and financed. As clinical evidence continues to expand beyond weight loss into cardiovascular disease, chronic kidney disease, obstructive sleep apnea, and metabolic dysfunction-associated steatohepatitis (MASH), GLP-1s are emerging as one of the most important pharmaceutical platforms of the decade.

The commercial opportunity is equally compelling. Morgan Stanley research projects the global GLP-1 market could approach $190 billion by 2035, driven by expanding indications, broader reimbursement, and growing patient adoption. Yet the real story extends well beyond pharmaceutical revenues. Widespread GLP-1 adoption is expected to reshape healthcare utilization, influence payer economics, accelerate investment in manufacturing capacity, and create ripple effects across medical devices, digital health, care delivery, and even consumer industries.

This report examines the structural forces driving the GLP-1 market, the competitive landscape among leading pharmaceutical companies, the next wave of innovation through oral therapies and new indications, and the broader implications for investors and healthcare executives. As obesity increasingly shifts from a chronic cost burden to a treatable condition, GLP-1 therapies are not simply creating a new blockbuster drug class—they are redefining where value will be created across the healthcare ecosystem.

The Next $190 Billion Pharmaceutical Market

The commercial trajectory of GLP-1 therapies has few precedents in modern healthcare. What began as a diabetes treatment has evolved into one of the fastest-growing pharmaceutical markets in history, fueled by obesity's recognition as a chronic disease rather than a lifestyle condition.

Morgan Stanley projects the global GLP-1 market could approach $190 billion by 2035, more than double the roughly $79 billion in sales recorded in 2025 and some $40 billion above its prior estimate, as new indications, broader reimbursement, and manufacturing expansion accelerate adoption. J.P. Morgan estimates that 25 million to 30 million Americans could be on GLP-1 therapies by 2030, up from around 5 million in 2023.

Several structural forces explain this growth.

First, obesity affects more than 1 billion people globally, yet pharmacological treatment penetration remains extremely low. Second, payers are gradually recognizing obesity as a driver of downstream healthcare costs rather than an isolated condition. Finally, pharmaceutical manufacturers—including Novo Nordisk, Eli Lilly and several emerging competitors—are investing tens of billions of dollars into manufacturing capacity to alleviate supply constraints that have limited demand.

Unlike previous blockbuster drugs, GLP-1s are expanding into an exceptionally large addressable market where prevalence continues to increase rather than decline. For investors, the opportunity is no longer simply about prescription growth—it is about one of the largest therapeutic platform expansions the pharmaceutical industry has experienced in decades.

Beyond Weight Loss: Building a Multi-Disease Platform

Perhaps the most important misconception surrounding GLP-1 therapies is that they are primarily weight-loss drugs.

Increasingly, they resemble a therapeutic platform capable of treating multiple chronic diseases that share common metabolic pathways.

Clinical evidence has already demonstrated meaningful benefits across cardiovascular disease, type 2 diabetes, chronic kidney disease, obstructive sleep apnea, and MASH. Several additional trials are evaluating Alzheimer's disease, addiction disorders, osteoarthritis, and even Parkinson's disease.

This expansion fundamentally changes the economics of the market.

Each successful indication broadens reimbursement eligibility, increases lifetime patient value, and strengthens physician adoption. Instead of competing for obesity patients alone, GLP-1 manufacturers are positioning their therapies across some of the largest disease categories in healthcare.

The implication for payers is equally significant. While annual treatment costs remain high, the potential reduction in expensive downstream events—including heart attacks, dialysis, liver transplantation, and hospitalizations—could materially improve long-term healthcare economics.

For investors, future value creation may depend less on additional weight-loss efficacy and more on which companies successfully secure the broadest portfolio of approved indications.

Obesity Becomes Pharma's Most Valuable Battleground

The GLP-1 market may appear to be a two-company race today, but the competitive landscape is evolving into one of the pharmaceutical industry's most strategically important battlegrounds.

Novo Nordisk and Eli Lilly currently dominate the market through blockbuster therapies including Wegovy, Ozempic, Zepbound, and Mounjaro. Years of clinical leadership, manufacturing scale, and commercial execution have created significant barriers to entry, allowing both companies to capture the vast majority of today's market.

However, competition is no longer defined solely by commercial sales—it is increasingly driven by pipeline value. Deloitte estimates that obesity now represents the largest source of pharmaceutical pipeline value, surpassing oncology for the first time. It also finds that, across every therapy area, the top three companies control more than half of projected pipeline value—a concentration that underscores both the strength of today's market leaders and the challenge facing new entrants.

This concentration is unlikely to remain unchanged. Roche, Amgen, AstraZeneca, Pfizer, Structure Therapeutics, Viking Therapeutics, and several biotechnology companies are investing heavily in next-generation obesity therapies, including combination treatments, oral formulations, and longer-acting molecules designed to differentiate on efficacy, tolerability, or convenience.

Rather than competing over a single blockbuster drug, the industry is transitioning toward a platform-based market where sustained innovation, manufacturing capacity, lifecycle management, and expansion into new disease indications will determine long-term leadership. As the obesity market matures, competitive advantage will depend not only on clinical outcomes but also on the ability to continuously expand the therapeutic and commercial potential of GLP-1-based medicines.

The Ripple Effect Across the Healthcare Ecosystem

The largest economic impact of GLP-1 therapies may occur outside pharmaceutical companies.

As obesity prevalence declines among treated populations, healthcare utilization is expected to shift across multiple sectors.

Medical device manufacturers are already adapting to lower procedural volumes in bariatric surgery while increasing investment in metabolic monitoring technologies. Orthopedic providers could benefit from healthier patients becoming eligible for joint replacement procedures. Sleep medicine companies may experience changing demand as obstructive sleep apnea becomes increasingly treatable through pharmacotherapy.

Digital health companies are developing GLP-1 companion platforms focused on patient adherence, nutrition coaching, behavioral modification, and long-term monitoring. Employers and insurers are experimenting with new reimbursement models designed to balance short-term drug costs against future reductions in healthcare expenditures.

Outside healthcare, ripple effects extend into food manufacturers, fitness companies, apparel brands, and consumer packaged goods as patient behavior changes.

Rather than creating isolated pharmaceutical winners, GLP-1s are redistributing value throughout the broader healthcare economy.

The Next Adoption Catalyst

Injectable therapies have proven clinical efficacy, but they also represent one of the industry's largest adoption barriers.

Many eligible patients remain reluctant to initiate long-term injectable treatment despite demonstrated benefits.

Oral GLP-1 therapies could fundamentally change this dynamic.

Companies including Novo Nordisk, Eli Lilly and Pfizer are investing heavily in oral formulations designed to improve convenience, increase physician prescribing, and simplify chronic treatment adherence.

According to PwC, oral therapies could significantly expand the addressable patient population by reducing psychological barriers associated with injections while improving scalability across primary care settings.

Oral formulations may also improve global market penetration, particularly in countries where specialist access remains limited.

If injectable GLP-1s created the obesity market, oral therapies could ultimately transform it into a primary care category comparable to statins or hypertension medications.

Where Value Will Be Created Next

The investment opportunity surrounding GLP-1s extends far beyond pharmaceutical manufacturers.

Healthcare investors should increasingly evaluate second-order beneficiaries positioned to capitalize on broader metabolic health transformation.

Potential beneficiaries include:

• Contract manufacturers expanding peptide production capacity

• Digital health platforms supporting long-term adherence

• Diagnostic companies focused on metabolic disease

• Remote patient monitoring providers

• Medical nutrition businesses

• AI-powered chronic disease management platforms

• Employers and insurers capable of capturing long-term cost savings

Conversely, sectors highly dependent on obesity-related procedures or chronic disease utilization may face structural pressure if widespread adoption continues.

The defining investment question is no longer whether GLP-1 therapies succeed.

It is which parts of the healthcare value chain will capture the largest share of the economic value they create.

Bottom Line

GLP-1 therapies are becoming much more than the next blockbuster drug class.

They represent a structural shift toward treating metabolic disease before it progresses into costly chronic illness. As clinical indications expand, manufacturing scales, and oral therapies improve accessibility, the industry is entering a new phase where value creation extends well beyond pharmaceutical revenues.

For healthcare investors, the biggest winners may not simply be the companies selling GLP-1 drugs, but those positioned to benefit from a healthcare system increasingly organized around prevention rather than treatment.

Sources

Morgan Stanley. “Obesity Drugs Are Scaling Fast,” April 2026. morganstanley.com/insights/articles/glp1-weight-loss-market-may-double-190-billion-2035

J.P. Morgan. “How Demand for (and Supply of) Weight-Loss Drugs Is Playing Out in 2026,” February 2026. jpmorgan.com/insights/global-research/current-events/obesity-drugs

Deloitte. “Navigating the GLP-1 Boom: Measuring the Return from Pharmaceutical Innovation,” May 2026. deloitte.com/ch/en/Industries/life-sciences-health-care/perspectives/navigating-the-glp-boom.html

PwC. “Oral GLP-1: How to Win in the Next GLP-1 Era,” February 2026. pwc.ch/en/insights/health-industries/oral-glp-1.html

BCG. “GLP-1s Are Shaking Up Patient Care. Medtech Will Need to Adapt,” May 2025. bcg.com/publications/2025/glp-1s-shaking-up-patient-care-medtech-needs-to-adapt

Forbes. Sindhya Valloppillil, “The GLP-1 Revolution — Everyone and Their Moms Are on GLP-1s,” February 2025. forbes.com/sites/sindhyavalloppillil/2025/02/25/the-glp-1-revolution---everyone-and-their-moms-are-on-glp-1s/